Solventum (NYSE:SOLV) Cut to "Hold" at Wall Street Zen

Key Points

• Wall Street Zen downgraded Solventum from “Buy” to “Hold.” However, the broader analyst consensus remains “Moderate Buy,” with eight Buy, four Hold, and one Sell rating.
• Several analysts recently raised their price targets to between $95 and $105, while the consensus target is $91.64; shares opened at $89.64, near their 52-week high of $90.00.
• Solventum exceeded quarterly expectations, reporting adjusted earnings of $2.55 per share versus the $1.91 estimate and revenue of $2.21 billion versus $2.15 billion expected. The company maintained fiscal 2026 EPS guidance of $7.10–$7.20.

Solventum (NYSE:SOLV - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a report issued on Saturday.

Other equities research analysts have also recently issued research reports about the company. Stifel Nicolaus increased their price target on Solventum from $90.00 to $100.00 and gave the company a "buy" rating in a research note on Thursday, August 6th. Wedbush raised their price target on shares of Solventum from $94.00 to $101.00 and gave the stock an "outperform" rating in a report on Thursday, August 6th. BTIG Research boosted their price objective on Solventum from $91.00 to $95.00 and gave the company a "buy" rating in a research note on Thursday, August 6th. KeyCorp upped their target price on Solventum from $93.00 to $102.00 and gave the company an "overweight" rating in a research report on Thursday, August 6th. Finally, Piper Sandler upped their target price on Solventum from $92.00 to $105.00 and gave the company an "overweight" rating in a research report on Thursday, August 6th. Eight equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $91.64.

Solventum Price Performance

Shares of NYSE:SOLV opened at $89.64 on Friday. The company has a debt-to-equity ratio of 1.00, a quick ratio of 0.74 and a current ratio of 1.02. Solventum has a 52 week low of $62.38 and a 52 week high of $90.00. The firm has a market cap of $15.26 billion, a PE ratio of 10.96, a price-to-earnings-growth ratio of 1.14 and a beta of 0.60. The firm's fifty day moving average is $80.91 and its 200-day moving average is $75.05.

Solventum (NYSE:SOLV - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $2.55 earnings per share for the quarter, beating analysts' consensus estimates of $1.91 by $0.64. The business had revenue of $2.21 billion during the quarter, compared to the consensus estimate of $2.15 billion. Solventum had a return on equity of 25.09% and a net margin of 17.26%.Solventum's quarterly revenue was up 2.2% on a year-over-year basis. During the same period in the prior year, the business posted $1.69 earnings per share. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. Sell-side analysts predict that Solventum will post 7.22 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of SOLV. CrossGen Wealth LLC bought a new stake in Solventum during the fourth quarter worth $25,000. Measured Wealth Private Client Group LLC bought a new position in Solventum during the 3rd quarter valued at $25,000. Clearstead Trust LLC boosted its holdings in Solventum by 61.0% during the 1st quarter. Clearstead Trust LLC now owns 396 shares of the company's stock worth $26,000 after acquiring an additional 150 shares during the last quarter. CYBER HORNET ETFs LLC purchased a new position in Solventum during the 2nd quarter worth $28,000. Finally, Modus Advisors LLC purchased a new position in Solventum during the 4th quarter worth $30,000.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source